F
Feng Shen
Researcher at Second Military Medical University
Publications - 403
Citations - 12498
Feng Shen is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 46, co-authored 313 publications receiving 8315 citations.
Papers
More filters
Journal ArticleDOI
Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection.
Fabio Bagante,Gaya Spolverato,Katiuscha Merath,Matthew J. Weiss,Sorin Alexandrescu,Hugo Marques,Luca Aldrighetti,Shishir K. Maithel,Carlo Pulitano,Todd W. Bauer,Feng Shen,George A. Poultsides,Olivier Soubrane,Guillaume Martel,B. Groot Koerkamp,Alfredo Guglielmi,Itaru Endo,Timothy M. Pawlik +17 more
TL;DR: A log-model Classification and Regression Tree-derived tumor burden score may be a better tool to estimate prognosis of patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma and other factors associated with prognosis.
Journal ArticleDOI
Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis
Shuzhen Chen,Zihui Dong,Pinghua Yang,Xian-ming Wang,Guangzhi Jin,Han Yu,Lei Chen,Liang Li,Liang Tang,Shilei Bai,He-Xin Yan,Feng Shen,Wen-Ming Cong,Wen Wen,Hongyang Wang +14 more
TL;DR: Data indicates that HMGB1 could serve as a novel prognostic biomarker and potential therapeutic target for HBV-related HCC through translocation and secretion of high-mobility group box 1 from tumor cells via calcium dependent cascades.
Journal ArticleDOI
Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels
TL;DR: A preoperative HBsAg level of 1000 IU/mL or greater is an independent risk factor for HCC recurrence in patients with low HBV DNA levels, and when compared with hepatitis B e antigen status, HBs Ag level better predicted recurrence of HCC.
Journal ArticleDOI
A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B
Tian Yang,Hao Xing,Guoqiang Wang,Nianyue Wang,Miaoxia Liu,Cunling Yan,Huijun Li,Lianhua Wei,Shunjun Li,Zhuping Fan,Ming Shi,Wei Chen,Shangli Cai,Timothy M. Pawlik,Andrew Soh,Agim Beshiri,Wan Yee Lau,Meng-Chao Wu,Yijie Zheng,Feng Shen +19 more
TL;DR: It is demonstrated that a web-based calculator including age, sex, AFP, and PIVKA-II accurately predicted the presence of HCC in patients with chronic hepatitis B (CHB) and was validated in the validation cohort.
Journal ArticleDOI
Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.
Alessandro Vitale,Alessandro Cucchetti,G.L. Qiao,Matteo Cescon,Jun Li,Rafael Morales,Anna Chiara Frigo,Yong Xia,F. Tuci,Feng Shen,U. Cillo,A.D. Pinna +11 more
TL;DR: Based on NTT analysis, the adopted time horizon is the main factor influencing the benefit of LT in patients with resectable HCC and Child A cirrhosis.